EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Can Fite Biopharma's Enterprise Value is €208.74 Mil.
Can Fite Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-7.71 Mil. Therefore, Can Fite Biopharma's EV-to-FCF for today is -27.09.
The historical rank and industry rank for Can Fite Biopharma's EV-to-FCF or its related term are showing as below:
STU:CF5'
s EV-to-FCF Range Over the Past 10 Years
Min: -6.53 Med: -0.47 Max: 0.66
Current: 0.01
During the past 13 years, the highest EV-to-FCF of Can Fite Biopharma was 0.66. The lowest was -6.53. And the median was -0.47.
STU:CF5's EV-to-FCF is ranked better than 98.48% of 330
companies
in the Biotechnology industry
Industry Median: 16.3
vs STU:CF5: 0.01
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Can Fite Biopharma (STU:CF5) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Can Fite Biopharma's PE Ratio (TTM) for today is calculated as:
Can Fite Biopharma's share price for today is €101.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Can Fite Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-3.230.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Can Fite Biopharma EV-to-FCF Related Terms
Can Fite Biopharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Can Fite Biopharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Can Fite Biopharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Can Fite Biopharma EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Can Fite Biopharma's EV-to-FCF falls into.
Can Fite Biopharma's current Enterprise Value is €208.74 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Can Fite Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-7.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Can Fite Biopharma (STU:CF5) has a EV-to-FCF of -27.09 as of Jul. 06, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Can Fite Biopharma and its competitors. According to the industry distribution chart, Can Fite Biopharma ranks #5 out of 330 companies in the Biotechnology industry, placing it in the top 1.5%.
Is Can Fite Biopharma's EV-to-FCF too high?
Can Fite Biopharma's current EV-to-FCF is -27.09. Based on the distribution chart, Can Fite Biopharma ranks #5 out of 330 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Can Fite Biopharma has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Can Fite Biopharma ranks #5 out of 330 companies for EV-to-FCF. This places Can Fite Biopharma in the top 2% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 16.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.30, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Can Fite Biopharma and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Can Fite Biopharma's current EV-to-FCF is -27.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Can Fite Biopharma (STU:CF5) has a current EV-to-FCF of -27.09. The stock's GF Value™ is €163.41, compared to a current price of €101.00 — trading 38.2% below its estimated fair value. The current EV-to-FCF is -27.09. Can Fite Biopharma's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Can Fite Biopharma (STU:CF5), the current EV-to-FCF is -27.09 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Can Fite Biopharma (STU:CF5) Overvalued in 2026?
Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued.
The current stock price of €101.00 is trading 38.2% below its estimated GF Value™ of €163.41.
Key valuation signals for STU:CF5:
EV-to-FCF: -27.09
GF Value™: €163.41 vs. price of €101.00 (38.2% below fair value)
No single metric tells the full story. See the STU:CF5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
52GF Score
Get the complete analysis for STU:CF5
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CF5 has been successfully added to your 
